Your session is about to expire
← Back to Search
Telehealth Support for Liver Cirrhosis
N/A
Waitlist Available
Led By Vandana Khungar, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights
Study Summary
This trial looks at how a telehealth intervention may help reduce hospital readmissions for cirrhotic patients. Patients will receive daily texts & weekly phone calls for 90 days. Rates & days to readmission will be compared between groups.
Who is the study for?
This trial is for cirrhosis patients at the University of Pennsylvania Hospital who can read and consent in English, have a cell phone to receive texts, or have someone who can handle communications for them. It's not for non-cirrhotic individuals, those with severe other diseases expected to be fatal within six months, without texting capability, unable to consent in English, post-liver transplant patients, or those using illicit substances.Check my eligibility
What is being tested?
The study tests if a telehealth intervention with daily texts and weekly calls after hospital discharge reduces readmissions over 90 days compared to standard care. Participants are randomly placed into two groups: one receives the telehealth follow-up; the other gets usual care.See study design
What are the potential side effects?
Since this trial involves a non-medical intervention (telehealth communication), there are no direct medical side effects associated with drugs or procedures. However, participants may experience privacy concerns or stress related to frequent communication.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 90 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
A change in readmission rates of cirrhotic patients
Secondary outcome measures
A difference in patient or caregiver satisfaction post-discharge.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Daily telehealth follow-upExperimental Treatment1 Intervention
The intervention arm will receive a simple telehealth intervention utilizing the Way to Health Platform engineered at the University of Pennsylvania. This platform will be used to send daily SMS messages to patients for 90 days following discharge and alert the research team to changes in patients' status. In addition, the patients in the intervention arm will receive a weekly phone call administered by members of the research team to assess their overall progress and well-being.
Group II: Standard of care follow-upActive Control1 Intervention
Standard of care
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intervention
2011
Completed Phase 4
~73780
Find a Location
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
1,992 Previous Clinical Trials
42,875,083 Total Patients Enrolled
Vandana Khungar, MDPrincipal InvestigatorUniversity of Pennsylvania
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You do not have liver cirrhosis.You have severe symptoms from another medical condition or have a complicated medical history.You are currently using illegal drugs or drinking alcohol regularly.You are not eligible if you have been discharged to hospice or if you have a serious illness (like advanced heart disease or cancer) that is likely to cause death within the next 6 months.
Research Study Groups:
This trial has the following groups:- Group 1: Daily telehealth follow-up
- Group 2: Standard of care follow-up
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger